Neural Effects of Green Tea Extract on Dorsolateral Prefrontal Cortex
NCT ID: NCT01615289
Last Updated: 2012-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2010-07-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Catechin High Contain Greentea Extract on Improvement of Cognitive Function
NCT03826017
Understanding the Effects of Daily Tea Consumption on Attention, Sleep, and Mood, in Healthy Adults
NCT06224569
Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults
NCT00981292
Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables
NCT02388672
Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients
NCT02731495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A double-blind, controlled, within-subject study with counterbalanced order of substance administration using an established protocol (6-8) was conducted over 4 sessions (250 ml or 500 ml Rivella green® (including green tea extract; RG), 250 or 500 ml Rivella blue® (RB). Each participant was scanned four times with a one-week interval between scans. The order of substance administration across sessions was counterbalanced across subjects, such that equal numbers followed each substance sequence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Green tea extract, 250 ml
Single intragastric instillation of 250 ml green tea extract
Single intragastric instillation of 250 ml green tea extract
Intragastric instillation by feeding tube
Green tea extract, 500 ml
Intragastric instillation of 500 ml green tea extract solution
Single intragastric instillation of 500 ml green tea extract
Intragastric instillation by feeding tube
Control solution, 250 ml
Intragastric instillation of 250 ml control solution
Single intragastric instillation of 250 ml control solution
Intragastric instillation by feeding tube
Control solution, 500 ml
Single intragastric instillation of 500 ml control solution
Single intragastric instillation of 500 ml control solution
Intragastric instillation by feeding tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single intragastric instillation of 250 ml green tea extract
Intragastric instillation by feeding tube
Single intragastric instillation of 500 ml green tea extract
Intragastric instillation by feeding tube
Single intragastric instillation of 250 ml control solution
Intragastric instillation by feeding tube
Single intragastric instillation of 500 ml control solution
Intragastric instillation by feeding tube
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christoph Beglinger
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christoph Beglinger, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Basel, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EKBB 32/09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.